ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2025
Modeling Reporting Delay in Cancer Incidence Counts in the Evolving US and Canadian Population-Based Cancer Registry Environment.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pancreatic Neuroendocrine and Exocrine Cancer Incidence, and Stage at Diagnosis Before, During, and After the COVID-19 Pandemic, United States, 2019-2022.Journal of registry management · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer incidence data collected by cancer registries in the United States and Canada are submitted to the North American Association of Central Cancer Registries, which publishes annual case counts for the two countries. To allow time to collect and report cases, counts for a given diagnosis year are initially published two years after the end of that year and updated annually. Initial counts typically underreport cases compared with updated counts due to reporting delays, potentially biasing estimated incidence trends.
methodsExisting methods for estimating "delay-adjusted" counts are modified for this heterogeneous group of registries exhibiting different patterns of reporting delay. The new method can be applied to individual registries and combined to produce delay-adjusted rates for the entire population, as well as for geographic or demographic subpopulations.
resultsSteps involved in estimating delay-adjusted counts are illustrated for liver and intrahepatic bile duct cancer in White males, in which delay-adjusted rates exhibit a stabilized trend, in contrast to the rapid decline seen in observed (unadjusted) rates. Additionally, the new delay model reveals reporting delays varying across cancer sites, race, and ethnicity. Finally, an extended model provides validated delay-adjusted rates from preliminary data that reduces reporting time from 2 years to 1 year.
conclusionsAdjusting for reporting delay provides more accurate estimates of cancer incidence trends. The proposed method addresses practical issues of model implementation and continues the evolution of delay adjustment in cancer registries. IMPACT: The new model extends the use of delay adjustment to an important source of cancer surveillance statistics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.